Publications by authors named "C L Feeney"

Introduction Pediatric to adult health care transition (HCT) is critical to maintaining the health and wellness of patients, and pediatric and adult providers often do not feel prepared to shepherd patients through this process. Methods  We designed an HCT curriculum consisting of nine podcasts paired with existing ambulatory experiential learning opportunities for internal medicine-pediatric residents (n=6). Before and after the curriculum we evaluated resident HCT self-assessment and resident performance working with a standardized patient (SP) and standardized parent in a novel objective structured clinical examination (OSCE) station designed to assess HCT skills.

View Article and Find Full Text PDF

Increasing soil organic carbon (SOC) confers benefits to soil health, biodiversity, underpins carbon sequestration and ameliorates land degradation. One recommendation is to increase SOC such that the SOC to clay ratio (SOC/clay) exceeds 1/13, yet normalising SOC levels based on clay alone gives misleading indications of soil structure and the potential to store additional carbon. Building on work by Poeplau & Don (2023) to benchmark observed against predicted SOC, we advance an alternative indicator: the ratio between observed and "typical" SOC (O/T SOC) for pan-European application.

View Article and Find Full Text PDF

Objectives: The clinical activity score (CAS) and European severity scale (ESS) are established clinical tools to assess thyroid eye disease (TED) but are limited in terms of subjectivity and their reliability in non-Caucasian individuals, and can underestimate significant disease in the posterior orbit. Preliminary data from pilot studies have shown that diffusion-weighted imaging (DWI) using extraocular muscle (EOM) apparent diffusion coefficient (ADC) measurements may provide complementary information in TED. This study expands on previous research to assess for correlations between clinical scores and EOM-ADCs in stratifying disease activity and severity in a large patient cohort from an ethnically diverse population.

View Article and Find Full Text PDF
Article Synopsis
  • - Abrocitinib is an FDA-approved oral medication for treating moderate-to-severe atopic dermatitis (AD) in both adults and adolescents, and it has proven to be effective in clinical trials with a good safety profile over time.
  • - A 200-mg daily dose of abrocitinib offers quicker relief from itching and better skin improvement compared to dupilumab, but monitoring for potential side effects is crucial due to risks associated with all oral JAK inhibitors.
  • - The use of abrocitinib is appropriate for qualified patients needing systemic AD therapy, though caution is advised for specific populations such as older adults and those with certain health risks, with a recommendation to start with a lower 100-mg dose in
View Article and Find Full Text PDF

Introduction: Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocitinib 100 mg/day and assessed the effect of an abrocitinib dose increase on platelet counts.

Methods: Analysis included the phase 3 trials JADE MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), and TEEN (NCT03796676).

View Article and Find Full Text PDF